Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation

This study has been completed.
Sponsor:
Collaborator:
Gilead Sciences
Information provided by (Responsible Party):
Soad Bekheit, North Shore Long Island Jewish Health System
ClinicalTrials.gov Identifier:
NCT01590979
First received: April 27, 2012
Last updated: August 18, 2015
Last verified: August 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2015
  Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)